BioSpace News Archive

In early November 2019, the Company reported topline results from the Phase III P301 trial in patients 6 to 11 years.

Equillium initiated the EQUALISE Phase 1b study of itolizumab in patients with lupus and lupus nephritis in September 2019.

Health Canada is advising Canadians that the following products may pose serious health risks. For more information, including what Canadians should do, visit the online safety alert.

Revenue was $32.8 million in the quarter compared to $24.8 million in the same period in the prior year, an increase of 33%.

Flores to succeed Kathy McElligott who is retiring February 3, 2020

City of Hope physicians and researchers at the American Society of Hematology (ASH) meeting in Orlando presented research on novel chimeric antigen receptor (CAR) T therapy and other potential new therapies for blood cancers, as well as a comprehensive report on long-term health problems bone marrow transplant (BMT) survivors face and prevention efforts that can be taken.

Constellation expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering.

The gross proceeds from the offering, before deducting underwriting discounts and offering expenses, were approximately $115.0 million.

Highlights Developments in Key Holdings Including Rafael Pharmaceuticals

Initial results from phase 2 study evaluating an investigational use of luspatercept-aamt in myelofibrosis-associated anemia showed promising clinical activity – companies plan to initiate pivotal, phase 3 study called INDEPENDENCE in 2020